Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Thanks kdonkey1000 - yes that was a typo by me. My imagination isn’t up to yours - never thought that stimgel might stand for stimulating gel. Perhaps I too, like ndr50, need to get out more ??
Do we know why the product is being marketed as Eroxon Simgel not simply Eroxon ?
* Having read through the webinar's agenda and given the professional stature of participants
I have today received my confirmation to attend next week's webinar as follows:
Details
The webinar will provide an overview of the clinical data and clinical implications of Eroxon® Stimgel and what this means for you and your patients.
Eroxon® Stimgel
- Available over-the-counter in pharmacies providing fast access to patients and reducing workload in General Practice and Pharmacy for patients that typically need to be referred to a prescriber.
- Clinically proven as effective in two phase 3 trials conducted in Europe and the USA.
- Non-invasive topical application with minimal side-effects and no known adverse drug interactions.
- Fast-acting with 60% of erections reported within 10 minutes.
Webinar agenda
- Presentation by Prof. David Ralph on the background and clinical data behind Eroxon® Stimgel.
- Faculty Q&A where Prof. Annamaria Giraldi, Prof. David Ralph and Prof. Gerald Brock will answer questions posed by general practitioner Dr. Michael Smith on the clinical implications of Eroxon® Stimgel.
- Audience Q&A where the webinar audience will have the opportunity to submit questions to the expert panel.
Faculty:
Chair - Dr. Michael Smith: General Practitioner
Expert panel :
Prof. David Ralph: Urology Professor, President of the Sexual Advice Association, ESGURS Chairman, and advisor to NICE
Prof. Gerald Brock: Urology Professor and President of the ISSM
Prof. Annamaria Giraldi: Professor of Clinical Sexology and Senior Consultant Psychiatrist at The Sexological Clinic. Past president of the ISSM
-----------------
Having read through the webinar's agenda and given of participants for the Q & A sessions, I would expect it to be a very lively and informative meeting. Eroxon clearly will have to be recognised as a substantial new entry to this major market. Irrespective of the FDA's dragging its feet, it's clear to me as a very LTH, this is really excellent news for us and I foresee a major reappraisal of Futura's shares coming once this webinar publicity hits the markets.
Great news indeed - good luck to all those that have stuck it out and stayed the course.
GLA
I'm a LTH but want to hear what's happening to the market in the UK. Do we have any ideas when Coopers will release it here ?
The RNS is well crafted in my opinion - I have always said on the boards that the BoD were wrong to delay commercialisation whilst waiting on the FDA to reach a decision. The FDA does seem to be dragging its feet here - as we know that FUM has provided them their required data.
But sales are now happening and we can expect good reviews based on the extensive past trials, not least the 1000 cohort trial of several years back. Plus we have respected ED specialist David Ralph extolling its virtues. Hold steady and this will move forward.
Could be any number of reasons why meeting put back - from people absence like Naheed Memon as a non-executive director of the Company - to big news of new enterprises being delayed especially if it relates to Pak! stan given the turmoil in that country at moment with next month's supposed elections. Lots of speculation about possible deals in Balochistan an area which got ravaged by last year's floods.
It would be quite something if our small enterprise minnow called CORO was beneficially involved somehow - certainly good for the sp.
"This absolutely will rally strongly"
I'd like to think so too Moneysponge.
As a LTH I feel the time is right for this to turn and today at end of trading, someone bought 2,500,000 shares @ 1.61p so we're not alone with our positive thinking.
Davey50 - nice summing up with where we are with Woodbois.
1st quarter figures should be good - we know the year started well. And with LO and Pelham out of the way, surely this should be good for us sooner or later.
There's too much comment on this thread that's without any substance. The thread title itself is meaningless as there are no impressive buys. The BoD said we'd here in the 4th quarter the progress of the new tests ant here we are coming near to the end of this year's 1st quarter.
It's the BoD's responsibility to update shareholders regularly - but worse to fly a date that has now been missed by very many weeks. It's this lack of information that has killed the sp. In the absence of news, the market will always fear the worst. As a LTH from Concepta days, I too am feeling very concerned as to the lack of news.
I've assumed Miles Pelham sold out as a distressed seller. I met him a couple of years back and he was very positive with me about WBI in its post Obtala markets. But it's only an assumption on my part.
As for trading - WBI's financial figures continue to improve and with Gabon being politically stable - the outlook seems good imo.
Don't forget Cooper Consumer Health are holding a marketing webinar - when we looked at it a couple of weeks back I thought it was forecast to be 17th March but now looking at it today - they don't show a date but state it is end March (which would be Friday 31st). So, does anyone else remember differently - it looks like it has been put back 2 weeks.
I was able to register for it OK after the earlier problems some of us had been having entering our postcodes and requested a 'sample' in the tick box by the way !
Here's the link if it helps you
https://www.b-ad.fr/en/eroxon-essm-2023/
Like the storyline Chizzywizzy47 - welcome to LSE - with posts like yours I can't wait for your Chapter 2 :-)
This is a very good conference that Futura is attending - yes it is a poster presentation but I'm hoping that Ken James will be there to field enquiries but I can't see his name anywhere. However, and perhaps more importantly for soft-selling of Eroxon, Futura's longtime Consultant support Professor David Ralph is actually presenting in several slots for surgical penile implants etc of which he specialises in and so is well regarded in this field.
There are several presentations from him - shown as D Ralph and D.J. Ralph but I think they are the same person. You can see his background from his Harley Street offices:
http://www.david-ralph.co.uk/erectile-dysfunction
Altogether, this is another bit of excellent news for us LTHs and augers well for the share price. GLA
There was an unusually large buy this afternoon at 16.10 - 3,000,000 shares bought at 1.46p - has some info leaked ?
Let's hope it presages good news - like Boots stocking the DNA tests perhaps ?
BradSmith - with the price fall to sub 2p isn't anything to do with last Spring's ramping by what were almost criminal posters. Instead, there's been a persistent sell-down by Rhino Ventures of its previously massive holdings - and in the absence of any news about them, I'm assuming its distressed selling for reasons known only to themselves.
Looking back over the years, the sp has always bounced strongly on news - and then fallen back a little each day subsequently. I think this time the BoD has been much better in its publicity announcements the past months and so feel there's a good chance the sp will hold on to its gains. Long term in any case, the sp should steadily grow dependent solely on level of sales.
There were 3 large sells at close of trading Friday 12million and 2 x 50million shares shown as priced at £180k and £750k.
Yet the price held steady. These are likely to be either Rhino Ventures and/or Lombard Odier. I guess we’ll see an RNS this week.
It’s quite a mystery what’s happening here with WBI as they’re trading exceedingly well - could it be tax related as we’re coming to the end of this fiscal year in 6 weeks ?